No Data
Express News | Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target
Cognition Therapeutics Analyst Ratings
$CGTX Stock Is up 17% Today. Here's What We See in Our Data.
Express News | Cognition Therapeutics Says Masked Analysis Showed Participants Receiving Oral Zervimesine For At Least Least 6 Months Experienced Slower Lesion Growth Than Participants Receiving Placebo
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy
Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit
